TargetMol

Almonertinib hydrochloride

Product Code:
 
TAR-T5675
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T5675-1mg1mg£145.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5675-5mg5mg£227.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5675-10mg10mg£334.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5675-25mg25mg£524.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5675-50mg50mg£707.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
HS-10296 hydrochloride is a small molecule inhibitor of EGFR-activating mutations and T790M-resistant mutation with limited activity against wild-type EGFR.
CAS:
2134096-03-8
Formula:
C30H36ClN7O2
Molecular Weight:
562.12
Pathway:
JAK/STAT signaling; Angiogenesis; Tyrosine Kinase/Adaptors
Purity:
0.9801
SMILES:
Cl.COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C2CC2)c2ccccc12
Target:
EGFR

References

Wu S G , Shih J Y . Management of acquired resistance to EGFR TKI?targeted therapy in advanced non-small cell lung cancer[J]. Molecular Cancer, 2018, 17(1):38. Ivana S , David P . Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line[J]. Frontiers in Medicine, 2017, 3.